Table 6 New drugs for the treatment of hepatitis C in phase III study (combinations with peginterferon plus ribavirin, or DAA combinations)
From: Treatment of hepatitis C virus infection in the future
Combination with peginterferon plus ribavirin | ||
|---|---|---|
Drug name | Category | Company |
Daclatasvir (BMS-79002) | NS5A inhibitor | Bristol-Myers Squibb |
Simeprevir (TMC435) | Protease inhibitor | Janssen |
Sofosbuvir (GS-7977) | Polymerase inhibitor | Gilead |
DAA combinations | ||
Drug name/Category | Drug name/Category | Company |
ABT-450r/Protease inhibitor | ABT-267/NS5A inhibitor and/or ABT-333/Polymerase inhibitor | Abbott/Enanta |
Daclatasvir (BMS-79002)/ NS5A inhibitor | Asunaprevir (BMS-650032)/Protease inhibitor | Bristol-Myers Squibb |
Faldaprevir (BI201335)/ Protease inhibitor | GS-5885/NS5A inhibitor | Boehringer Ingelheim |
Sofosbuvir (GS-7977)/ Polymerase inhibitor | BI207127/Polymerase inhibitor | Gilead |
Sofosbuvir (GS-7977)/ Polymerase inhibitor | GS-5885/NS5A inhibitor | Gilead |